01. June 2022.
Hemofarm company has marked 62 years of successful operation and continuous growth under the slogan ‘Humanity is the Cure’. As the leading regional pharmaceutical company, Hemofarm looks upon caring for people’s health and promotion of humanity as its mission, indicating, by personal example, to their importance in the society.
‘Hemofarm is a legacy that we pass on from generation to generation, thus empowering our company. We have been constantly scoring a record-breaking production of medicines, while simultaneously preserving natural resources and operating in tune with the principles of sustainable development. It also involves caring for people, healthcare system, local community, and society in general. That is exactly the point – to work good for the better health of citizens, but also to help in other available ways. We must not forget that humanity is the cure, the special one that heals the body and the soul ‘, Dr Ronald Seeliger, CEO of the company, emphasized on the occasion of its anniversary.
From a small plant established in Vršac on 1 June 1960, with 30 employees at that time, Hemofarm has evolved to be a regional leader operating globally on four continents, with the current headcount of 3,600 people. After last year, when a record 287 million finished product packs were produced, Hemofarm has entered 2022 with even higher expectations - 300 million packs to come out of its plants this year, which would be a new production record of this company.
To mark the occasion, Stephan Eder, Executive Vice President of STADA Group in charge of European Markets and Germany, paid his first official visit to Hemofarm’s plants in Banjaluka and Vršac. ‘I am very glad to be here on this special day. I am aware that Hemofarm means a lot to patients, because it is a large and reliable provider of quality medicines that people can count on. I am impressed with how passionate and dedicated people at Hemofarm are in their approach to work, so that the medicines could reach the patients.’, Eder said.
Over the course of the past three decades, Hemofarm's laboratories have developed more than 300 pharmaceutical products registered throughout Europe and Asia, and 62 employees are currently engaged in the development of 46 new products. One of the biggest successes this year is the launch of ticagrelor, an extremely significant medicine in antiplatelet therapy, that Hemofarm developed in its laboratories, thus being the first company to launch it to the Serbian market after the originator.
Hemofarm has been constantly growing ever since its foundation, which would not have been possible without regular investments and constant innovations in pharmaceutical production. Since becoming a member of STADA group in 2006, this pharmaceutical company has invested as much as 385 million EUR in the modernization of its facilities, equipment, and new plants.
Reception for employees and children
The traditional reception that was held in Vršac-located factory to celebrate the anniversary has been marked by humanity this year: the company paid honour to its heroes among employees, jubilarians, voluntary blood donors, and food donors. In addition to health examinations provided to employees at several medical booths within the factory, an entertainment and educational program was organized for the children of employees this time. On this year’s company anniversary as well, in cooperation with the Blood Transfusion Institute of Vojvodina, Hemofarm employees voluntarily donated blood in a transfusion bus located inside the factory area. For this occasion, Hemofarm Foundation organized a special edition of the panel session ‘A Cup of Coffee with a Psychologist’ for employees.
